ECOVAXXIN® MG marketing authorisation application
Submitted EU marketing authorisation application for ECOVAXXIN® MG poultry vaccine against Mycoplasma gallisepticum.
Select text to share a quote on X · sign in to keep highlights & notes in your EAH notes
ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that it has submitted a Marketing Authorisation Application and supporting dossier to the European Medicines Agency (“EMA”) for ECOVAXXIN® MG, its live poultry vaccine targeting Mycoplasma gallisepticum.
ECOVAXXIN® MG is the second vaccine product from ECO’s proprietary R&D pipeline to be submitted for marketing authorisation to the EMA. It follows ECOVAXXIN® MS, the Company’s poultry vaccine against Mycoplasma synoviae, which was commercially launched in the EU in July 2026. If approved, ECOVAXXIN® MG will extend ECO’s poultry vaccine offering across major Mycoplasma infections and will sit alongside Aivlosin®, the Company’s market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry.
In March 2026, ECOVAXXIN® MG received a favourable safety assessment from the United States Department of Agriculture, marking an important step towards achieving marketing authorisation for the vaccine in the United States.
David Hallas, Chief Executive Officer of ECO Animal Health, said: “The submission of the EU dossier for ECOVAXXIN® MG is an important milestone for ECO and reflects the hard work and commitment of our R&D and regulatory teams. Following the EU approval and launch of ECOVAXXIN® MS, ECOVAXXIN® MG builds on our position in the prevention and treatment of Mycoplasma infection in poultry. Our regulatory plan remains in-line with expectations and we look forward to progressing through the EMA review process and advancing towards a planned launch, while in parallel continuing our work towards US marketing authorisation.”
Mycoplasma gallisepticum is a bacterial pathogen responsible for chronic respiratory disease in chickens which causes decreased egg production leading to major economic losses in poultry. The live strain of the bacteria used for ECOVAXXIN® MG is a naturally attenuated isolate shown to be safe for young chicks.
Cleaned text: letterheads, contacts and legal notices removed. Official copy: FCA National Storage Mechanism ↗ · Company filings. Not investment advice.